Evidence map›Paper›PMID 38591867›Full record

Trial reportJCO precision oncology2024

Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.

Monica F Chen, Zihe Song, Helena A Yu, Lecia V Sequist, Christine M Lovly, Edith P Mitchell, Jeffrey A Moscow, Robert J Gray, Victoria Wang, Lisa M McShane and 12 more

Open access · greenAbstract readClinical Trial, Phase IIAdaptive Clinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in JCO precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 0 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 11 institutions in 1 country.

Monica F ChenMemorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-7485-2463
Zihe SongDana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.
Helena A YuMemorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-0377-9510
Lecia V SequistMassachusetts General Hospital Cancer Center, Boston, MA.ORCID 0000-0002-8965-6991
Christine M LovlyVanderbilt-Ingram Cancer Center, Nashville, TN.ORCID 0000-0002-3641-6361
Edith P MitchellSidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA.
Jeffrey A MoscowCancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.
Robert J GrayDana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.ORCID 0000-0002-5724-4917
Victoria WangDana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.
Lisa M McShaneBiometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0001-8195-3206
Larry V RubinsteinBiometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-9720-9737
David R PattonCenter for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD.ORCID 0000-0003-3855-0166
P Mickey WilliamsFrederick National Laboratory for Cancer Research, Frederick, MD.ORCID 0000-0002-3309-5988
Stanley R HamiltonCity of Hope National Medical Center, Duarte, CA.ORCID 0000-0002-8331-1052
Yoshie UmemuraUniversity of Michigan Comprehensive Cancer Center, Ann Arbor, MI.ORCID 0000-0001-7137-661X
James V TricoliDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0003-3975-8516
Barbara A ConleyDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-1445-1684
Carlos L ArteagaUT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX.
Lyndsay N HarrisDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-9774-6719
Peter J O'DwyerUniversity of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-9302-4073
Alice P ChenDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-2919-4326
Keith T FlahertyMassachusetts General Hospital Cancer Center, Boston, MA.ORCID 0000-0002-3402-0478
National Cancer Institute · USDana-Farber Cancer Institute · USMassachusetts General Hospital · USMemorial Sloan Kettering Cancer Center · USCity Of Hope National Medical Center · USFrederick National Laboratory for Cancer Research · USSouthwestern Medical Center · USThomas Jefferson University · USUniversity of Michigan · USUniversity of Pennsylvania · USVanderbilt University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6M
SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
Statistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO, CONSTANTINE A. GATSONIS · 2014 to 2026
$111.2M
ECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · 2015 to 2026
$41.1M
Investigational Cancer Therapeutics Training Program (ICTTP)T32CA009207 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Omar Abdel-Wahab, Alexander Drilon · 1985 to 2026
$13.7M
Network Lead Academic Participating Site: Memorial Sloan Kettering Cancer CenterUG1CA233290 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CAROL AGHAJANIAN, Darren Feldman · 2019 to 2026
$10.2M
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6M
UT Southwestern NCI National Clinical Trials Network (NCTN) LAPS - Supplemental Funds YR4UG1CA233302 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI David Eric Gerber · 2019 to 2026
$6.4M
UM LAPs -UG1 GrantUG1CA233160 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ANNE F SCHOTT · 2019 to 2026
$5.4M
Sidney Kimmel Cancer Center LAPS Institutional CollaborationUG1CA233341 · NCI · THOMAS JEFFERSON UNIVERSITY · PI Steven Cohen, Mitchell Edelson · 2019 to 2026
$3.5M
Vanderbilt Network Lead Academic Participating Site for the NCTNUG1CA233270 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Kristen Keon Ciombor · 2019 to 2026
$3.5M
NCI NIH HHS P30 CA008748NCI NIH HHS T32 CA009207NCI NIH HHS U10 CA180794NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180888NCI NIH HHS U24 CA196172NCI NIH HHS UG1 CA233160NCI NIH HHS UG1 CA233180NCI NIH HHS UG1 CA233270NCI NIH HHS UG1 CA233290NCI NIH HHS UG1 CA233302NCI NIH HHS UG1 CA233341
6 · The paper itself

Abstract

purposeThe National Cancer Institute Molecular Analysis for Therapy Choice trial is a signal-finding genomically driven platform trial that assigns patients with any advanced refractory solid tumor, lymphoma, or myeloma to targeted therapies on the basis of next-generation sequencing results. Subprotocol E evaluated osimertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with

methodsEligible patients had

resultsA total of 19 patients were enrolled: 17 were evaluable for toxicity and 13 for efficacy. The median age of the 13 included in the efficacy analysis was 63 years, 62% had Eastern Cooperative Oncology Group performance status 1, and 31% received >three previous systemic therapies. The most common tumor type was brain cancers (54%). The ORR was 15.4% (n = 2 of 13; 90% CI, 2.8 to 41.0) and 6-month PFS was 16.7% (90% CI, 0 to 34.4). The two confirmed RECIST responses were observed in a patient with neuroendocrine carcinoma not otherwise specified (

conclusionIn this pretreated cohort, osimertinib did not meet the prespecified end point threshold for efficacy, but responses were seen in a neuroendocrine carcinoma with an

Indexed as

AcrylamidesAniline CompoundsAntineoplastic AgentsCarcinoma, NeuroendocrineCarcinoma, Non-Small-Cell LungIndolesLung NeoplasmsPyrimidinesErbB ReceptorsHumansMiddle AgedMutationNational Cancer Institute (U.S.)Protein Kinase InhibitorsUnited StatesAcrylamidesAniline CompoundsAntineoplastic AgentsErbB ReceptorsIndolesosimertinibProtein Kinase InhibitorsPyrimidines

Identifiers

PMID38591867
PMCPMC10896470
OpenAlexW4392521389

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.